[Clinical experience with bromperidol in chronic psychoses].
Bromperidol therapeutic efficacy, and tolerance was studied by means of a 3-month open trial on 25 chronic psychotic female inpatients from a room at San Juan ward for medium to extensive length of stay, The Braulio A. Moyano National Psychiatric Hospital, Buenos Aires. This drug was administered orally on a single 10- to 35 mg night dose. No effect whatsoever was observed on periodic catatonia. However, its being well-tolerated and effective on chronic psychotic patients, coupled to the "bonus" of a single daily dose, turns BP into a suitable alternative drug for Haloperidol when dealing with schizophrenia, and delusions with no deficitary evolution.
Bellomo
L E
LE
Facultad de Medicina UBA, Buenos Aires, Argentina.
Rosset
N
N
Tellarini
L
L
Forconesi
N
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007297:Inpatients; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy
D006220:Haloperidol; C006820:bromperidol
Experiencia clínica con Bromperidol en psicosis crónicas.